Analyzing Rhythm Pharmaceuticals (NASDAQ:RYTM) & Scinai Immunotherapeutics (NASDAQ:SCNI)

Scinai Immunotherapeutics (NASDAQ:SCNI) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Scinai Immunotherapeutics and Rhythm Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Rhythm Pharmaceuticals	1	3	18	0	2.77

Rhythm Pharmaceuticals has a consensus target price of $142.00, suggesting a potential upside of 23.46%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Scinai Immunotherapeutics.

Earnings & Valuation

This table compares Scinai Immunotherapeutics and Rhythm Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.49 million	0.36	-$8.31 million	$8.66	0.05
Rhythm Pharmaceuticals	$280.75 million	28.40	-$196.54 million	($2.90)	-39.66

Scinai Immunotherapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Scinai Immunotherapeutics and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Rhythm Pharmaceuticals	-69.03%	-171.16%	-43.00%

Volatility & Risk

Scinai Immunotherapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Summary

Scinai Immunotherapeutics beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.